Immunotherapy Approaches in Front-Line Advanced/Recurrent Endometrial Cancer

Statement of Need

Recent advances in molecular classification of endometrial cancer (EC) have opened the door to better identification of adjuvant treatments that are more effective. Understanding how PD-L1 and PD-1 inhibitors contribute to improved efficacy in addition to standard of care in the settings of mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease is important to knowing which patients will benefit most from immunotherapy strategies for upfront treatment plans. As trials are ongoing and data are released, clinicians need experts to translate the data, explaining how it may impact care currently or in the future. Unfortunately, clinicians are not confident in their ability to optimally integrate ICIs into routine adjuvant therapy for endometrial cancer. Having a solid foundation of evidence and knowledge gives clinicians the confidence to adopt novel therapies in practice.
During this informational podcast, leading international endometrial cancer experts, Drs. Richard Penson and Mansoor Raza Mirza, will discuss patient selection for upfront immunotherapy-based strategies, emerging front-line therapeutic approaches, and challenges adapting to the evolving standards of front-line care.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Develop treatment plans that incorporate ICI strategies for newly diagnosed advanced or recurrent EC

Financial Support

Supported by a joint educational grant from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Primary Audiences: Medical oncologists, gynecologic oncologists, physician assistants (PAs), nurses, nurse practitioners (NPs), and pharmacists working in oncology settings
Secondary Audiences: Gynecologists and primary care physicians (PCPs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours ( 0.05 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-148-H01-P ).

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 12/28/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics
Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche
Research Support: Intuitional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics
Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Dr. Mirza reports the following financial relationships:

Advisory Board: Allarity Therapeutics, Inc.; AstraZeneca; BIOCAD; BioNTech SE; Boehringer Ingelheim; Clovis Oncology; Daiichi-Sankyo; Eisai Inc.; Genmab; GSK; ImmunoGen, Inc.; Incyte; Karyopharm Therapeutics; Merck & Co., Inc./MSD; Mersana Therapeutics; Novartis; Regeneron Pharmaceuticals Inc.; Roche; Seagen Inc.; Takeda Pharmaceutical Company Limited; Tesaro; and Zai Lab
Consultant: Allarity Therapeutics Inc.; GSK; Karyopharm Therapeutics; Tesaro; and Zailab
Grants: Allarity Therapeutics Inc.; Apexigen; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GSK; Novartis; Tesaro; and Ultimovacs
Stock Shareholder (ownership interest): Options: Karyopharm Therapeutics and Sera Prognostics
Employment: Member of Board of Directors: Karyopharm Therapeutics and Sera Prognostics

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Thomas Mitchell (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-099-122823-90

Immunotherapy Approaches in Front-Line Advanced/Recurrent Endometrial Cancer

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience